ProfDermot Cox
Associate Professor
School of Pharmacy and Biomolecular Sciences
Orcid identifier0000-0003-1365-3396 (opens in a new tab)
- Associate ProfessorSchool of Pharmacy and Biomolecular Sciences
- +353-1-4022152 (Work)
- RCSI, Molecular & Cellular Therapeutics, 123 St Stephens Green, Dublin 2
RESEARCH OVERVIEW
My primary research interest is in both drug discovery and development of novel agents that target platelets. Below are the specific areas of interest
1. GPIIb/IIIa antagonists. GPIIb/IIIa antagonists were the first anti-integrin agents to be discovered. However, despite their great potential they proved not to be a commercial success. My research which was both pre-clinical and clinical, has focused on the properties of these agents that led to their failure and also the options for the discovery of more effective GPIIb/IIIa antagonists.
2. Aspirin resistance. Aspirin is an effective agent with proven efficacy in the prevention of myocardial infarction. However, there is a significant number of patients that fail to respond to aspirin treatment putting them at increased risk of myocardial infarction. We have performed a number of clinical trials to investigate the role of enteric coating and obesity on aspirin response. We have on-going trials further investigating this.
3. Platelet and immunity. There is a growing awareness that platelets are part of the innate immune system and are the primary responder to bacteria entering the bloodstream. Sepsis occurs when the response of the immune system to bacteria gets out of control. Viral haemorrhage fever (VHF) has much in common with sepsis except that it is caused by viruses such as Ebola or Dengue. My research looks at the role of platelets in sepsis and VHF and the potential for platelets as drug targets in these conditions.
4. Platelet-bacteria interactions. There are numerous different mechanisms by which platelets interact with bacteria. We are investigating the specific mechanisms involved in the interaction of platelets with Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus sanguinis, Streptococcus gordonii, Escherichia coli and Helicobacter pylori. We have identified multiple platelet receptors and their corresponding bacteria ligands that mediate these interactions.
5. FcRIIa drug discovery. FcRIIa is a receptor for the Fc portion of IgG. It is a key player in the innate immune system and plays a critical role in multiple diseases such as rheumatoid arthritis and other autoimmune diseases. Furthermore, it is found on platelets and plays a critical role in the platelet response to bacteria and viruses and is a potential drug target in sepsis and VHF. We have a drug discovery project underway and have synthesised small molecule inhibitors of FcRIIa with nanoMolar Kd. Currently we are performing lead optimisation studies.
6. Electronic health record systems. Prescribing errors such as using the wrong drug/dose or drug interactions are a major cause of morbidity and mortality. A cloud-based EHR allows for the potential of reducing these errors as it allows the physician and pharmacist to see the complete overview of the patients medication. Furthermore, it allows a rules-based approach to prescribing that reduces errors as well. I work with Acquis, a US-based, Irish IT company to develop a highly secure, patient-centric, cloud-based EHR.
1. GPIIb/IIIa antagonists. GPIIb/IIIa antagonists were the first anti-integrin agents to be discovered. However, despite their great potential they proved not to be a commercial success. My research which was both pre-clinical and clinical, has focused on the properties of these agents that led to their failure and also the options for the discovery of more effective GPIIb/IIIa antagonists.
2. Aspirin resistance. Aspirin is an effective agent with proven efficacy in the prevention of myocardial infarction. However, there is a significant number of patients that fail to respond to aspirin treatment putting them at increased risk of myocardial infarction. We have performed a number of clinical trials to investigate the role of enteric coating and obesity on aspirin response. We have on-going trials further investigating this.
3. Platelet and immunity. There is a growing awareness that platelets are part of the innate immune system and are the primary responder to bacteria entering the bloodstream. Sepsis occurs when the response of the immune system to bacteria gets out of control. Viral haemorrhage fever (VHF) has much in common with sepsis except that it is caused by viruses such as Ebola or Dengue. My research looks at the role of platelets in sepsis and VHF and the potential for platelets as drug targets in these conditions.
4. Platelet-bacteria interactions. There are numerous different mechanisms by which platelets interact with bacteria. We are investigating the specific mechanisms involved in the interaction of platelets with Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus sanguinis, Streptococcus gordonii, Escherichia coli and Helicobacter pylori. We have identified multiple platelet receptors and their corresponding bacteria ligands that mediate these interactions.
5. FcRIIa drug discovery. FcRIIa is a receptor for the Fc portion of IgG. It is a key player in the innate immune system and plays a critical role in multiple diseases such as rheumatoid arthritis and other autoimmune diseases. Furthermore, it is found on platelets and plays a critical role in the platelet response to bacteria and viruses and is a potential drug target in sepsis and VHF. We have a drug discovery project underway and have synthesised small molecule inhibitors of FcRIIa with nanoMolar Kd. Currently we are performing lead optimisation studies.
6. Electronic health record systems. Prescribing errors such as using the wrong drug/dose or drug interactions are a major cause of morbidity and mortality. A cloud-based EHR allows for the potential of reducing these errors as it allows the physician and pharmacist to see the complete overview of the patients medication. Furthermore, it allows a rules-based approach to prescribing that reduces errors as well. I work with Acquis, a US-based, Irish IT company to develop a highly secure, patient-centric, cloud-based EHR.
GRANTS
- FUNDED PROJECTBScATT 2026 PlacementsRCSI29 Jun 2026 - 31 Dec 2026
- FUNDED PROJECTNovel Therapeutics Targeting the FcgRIIa receptorIndustry - Cash20 May 2024 - 31 Dec 2026
- FUNDED PROJECTNovel Therapeutics Targeting the FcgRIIa receptorIndustry - In Kind20 May 2024 - 31 Dec 2026
- FUNDED PROJECTNovel Therapeutics Targeting the FcgRIIa receptorEnterprise Ireland20 May 2024 - 31 Dec 2026
- FUNDED PROJECTViral DIC - Targeting ImmunothrombosisEnterprise Ireland21 Dec 2023 - 20 Dec 2025
- FUNDED PROJECTStudy of rolE of PlateletS In Sepsis (SEPSIS)Health Research Board / HRB1 Dec 2022 - 31 Dec 2026
- FUNDED PROJECTInvestigation of the haemostatic and thrombotic potential of stored plateletsIndustry21 Jan 2021 - 20 Jan 2023People funded by this grant:
- SHIONOGI BV
- FUNDED PROJECTH2020 Information day and Partnering Day for Health 3-4 JulyEnterprise Ireland H2020 Support27 May 2019 - 26 Nov 2019
- GRANTH2020 travel grantEnterprise Ireland27 May 2019 - 26 Nov 2019
- FUNDED PROJECTLead optimisation of FcγRIIa antagonistsScience Foundation Ireland (SFI)1 Mar 2018 - 30 Apr 2019
- FUNDED PROJECTCHART application corodination grantEnterprise Ireland H2020 Support29 Jan 2018 - 24 Apr 2018People funded by this grant:
- Tracy R,
- Tracy R,
- Tracy R,
- Tracy R,
- Tracy R
- FUNDED PROJECTDiscovery of small molecule inhibitors of Fc≥RIIaIndustry1 Nov 2016 - 31 Oct 2020
- FUNDED PROJECT64th Annual meeting (stand alone) of the scientific and standardization committee (SSC) of the ISTH (2018)Science Foundation Ireland (SFI)6 May 2016 - 30 Sep 2018
- FUNDED PROJECT64th Annual Meeting of SSC of the ISTH 2018Failte Ireland1 May 2016 - 31 Jul 2018
- FUNDED PROJECTDevelopment of a novel assay for anfibatideIndustry1 May 2016 - 30 Jun 2020
- FUNDED PROJECTValidation of FcgRIIa as a target in sepsisIndustry1 Aug 2015 - 31 Jan 2017
- FUNDED PROJECTNovel serum biomarkers of plaque rupture in Patients presenting with Chest PainRoyal City of Dublin Hospital Trust1 Dec 2014 - 30 Jun 2016People funded by this grant:
- Andrew M
- FUNDED PROJECTDevelopment of proof-of-concept animal model for novel FcãRIIa antagonistsScience Foundation Ireland (SFI)1 Jan 2014 - 30 Sep 2015
- FUNDED PROJECTTargeting the platelet in infection and inflammationIrish Research Council IRC1 Nov 2012 - 30 May 2013
- FUNDED PROJECTBid to host SSC 2016Science Foundation Ireland (SFI)1 Apr 2012 - 30 Sep 2012
- FUNDED PROJECTBid to host 2014 SSC meeting in DublinScience Foundation Ireland (SFI)1 Apr 2010 - 31 Oct 2010
- FUNDED PROJECTA preliminary study on the efficacy of GBR600 in rat blood ex vivo as determined by the PFA-100Industry1 Feb 2009 - 30 Jun 2016
- FUNDED PROJECTDevelopment of FcãRIIa antagonists as novel anti-platelet agentsScience Foundation Ireland (SFI)1 Oct 2007 - 31 Dec 2011